Plain-English translation of NCT05911217 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new immunotherapy called CT041, which is made from your own immune cells that have been specially modified to fight pancreatic cancer. The treatment is designed to target a protein called Claudin18.2 that appears on pancreatic cancer cells. You would receive this medication after completing your standard chemotherapy to help prevent the cancer from coming back.
Pancreatic cancer is very serious and often comes back even after surgery and chemotherapy. Researchers believe that this new cell-based treatment could help your immune system better recognize and destroy any remaining cancer cells, potentially improving survival and giving patients like you better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
You would first undergo a procedure called leukapheresis, where doctors collect white blood cells from your blood. These cells are then sent to a laboratory to be modified into the new treatment. After the cells are ready, you would receive the medication as an infusion. The study involves visits to the clinic for treatment, blood tests, and monitoring to check how well the treatment works and watch for any side effects. The trial is enrolling about 20 people across multiple centers.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China